Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer
PressReleasePoint,
The trial did not meet the primary endpoint of progression- free survival vs. platinum-based chemotherapy AstraZeneca and MSD…